Abstract
Introduction
The human immunodeficiency virus type 1 (HIV-1) is the primary cause of the acquired immunodeficiency syndrome (AIDS), which is a slow, progressive and degenerative disease of the human immune system. HIV-1 is a lentivirus belonging to the retrovirus family. The virus is diploid and contains two plus-stranded RNA copies of its genome. The development of possible methods that can delay progression of the infection or block replication of HIV-1 in infected individuals has been the subject of dedicated research efforts over the past decades. One important issue is that HIV-1 makes use of the replication machinery of the host cell, which minimizes the number of potential viral targets. On the other hand, the close host-virus relationship limits the evolutionary freedom for the viral components that interact with the host molecules [1] . Integration of viral DNA into the host chromosome is a necessary process in the HIV replication cycle [2] . The key steps of DNA integration are carried out by the viral integrase protein, which, along with protease and reverse transcriptase, is one of three enzymes encoded by HIV. Combination antiviral therapy with protease and reverse transcriptase inhibitors has demonstrated the potential therapeutic efficacy of antiviral therapy for treatment for AIDS [3] . Since HIV integrase has no direct cellular counterpart it presents itself as an attractive target for therapeutic intervention [4] . Unlike the retroviral reverse transcriptase and protease enzymes, successful drug candidates based on the inhibition of integrase have yet to emerge despite the multitude of laboratories working on the problem [5] . The objective of this study is to discover new analogs with improved potency, physiochemical/metabolic properties and toxic effects, which can stand as potential inhibitors of AIDS.
Materials and Methods
For the present study bioinformatics tools, biological databases like PubMed, Drug Bank, PDB (Protein Data Bank) and software's like Molegro Virtual Docker, ACD ChemSketch, Pharma Algorithms were used.
The structure of HIV-1 integrase catalytic domain was retrieved from Protein data bank (PDB) (PDB id: 1BL3) (http://www.pdb.org). It is a 160 residues long protein and contains three domains, an N-terminal HH-CC zinc finger domain believed to be partially responsible for multimerization, a central catalytic domain and a C-terminal domain. Both the Central catalytic domain and C-terminal domains have been shown to bind both viral and cellular DNA. Currently no crystal structure data exists with Integrase bound to its DNA substrates. Biochemical data and structural data suggest that integrase functions as a dimer or a tetramer [6] . The structures of the drugs Raltegravir and Elvitegravir were obtained from Drug Bank (www.drugbank.ca) and KEGG Drug (www.genome.jp/kegg/drug) respectively. Using ACDLABS/ChemSketch (www.acdlabs.com) the 2D structures of the analogues of these drugs were sketched. The analogs were screened for their physiochemical properties at FAF drugs. The analogs that do not follow Lipinski's rules are discarded. The selected analogs are then screened for their bioactivity and toxicity under PASS software. The selected analogs were then searched against various chemical structure databases for similarity with a existing structure. The databases taken in this step are: PubChem (pubchem.ncbi.nlm.nih.gov), KEGG, Molsoft (MolCart) (www.molsoft.com/molcart.html), Hic-Up (xray.bmc.uu.se/hicup/), and ChemBank (chembank.broadinstitute.org/). No similarity has been detected. The analogs are then subjected to molecular dynamics analysis in ChemBio3D Ultra under optimum conditions. The screened analogs were then subjected to Pharma Algorithm predict various pharmacological effects like oral bioavailability, protein binding etc. The Molecular Docking is performed in Molegro Virtual Docker (MVD) (http://www.molegro.com/). Possible active sites and cavities were detected for Chain A of 1BL3 using Molegro Virtual Docker. The following Parameters were used for Cavity Detection: 
Result

Result of Active Site Prediction and Cavity Detection
The structure of HIV-1 integrase catalytic domain (PDB id: 1BL3) is 160 residues long and contains three chains: A, B and C. Catalytic core domain is present between 50 -212 residues [7] . The position of the active site are Thr (T) =66. Asp (D) =64,116. Val (V) =77. Glu (E) =15 Lys (K) =159 [8, 9] . Active sites and cavities were detected for Chain A of 1BL3 using Molegro Virtual Docker. 
Result of Molecular Docking:
The Molecular Docking is performed in Molegro Virtual Docker (MVD) .The following Parameters were used for Docking using Molegro Virtual Docker. Docker uses the MolDock docking engine to predict ligand -protein interactions. MolDock is based on a new hybrid search algorithm, called guided differential evolution [10] . The imported ligands were manually checked before docking and corrected in those cases were it had failed. Water molecules with the protein structures were excluded from the docking experiments, The docking is then allowed to run for some time for Raltegravir and Elvitegravir analogs (remained after virtual screening) respectively with the target protein. The poses having the good MolDock and Docking score are selected for the further analysis. Docking results tabulated between HIV integrase and the conventional drug Raltegravir (Table  1) and Elvitegravir (Table 2) analogs are shown below. 
Result of Pharma algorithm
Pharma algorithm is a tool for in silico physicochemical, ADME, Metabolism, and Toxicology screening and prediction. The results for Raltegravir (Table 5) and Elvitegravir (Table 6) analogs are shown below 
Conclusion
From the molecular docking result carrying out using Molegro virtual docker, the best four analog form each inhibitor ( Raltegravir-RL-40,RL-13, RL -10, RL-9 ; Elvitegravir-EL-27,EL-47,EL-28, EL-21 ) based on the mol dock score and the docking score were selected. The close contacts shows that there is a high possibility of interaction of these analogs with the amino acids of the active site of the protein .These analogs also show better bioavailability (RL 40 ; EL47) , protein binding (RL 10, EL 7) ,solubility (EL7, RL 10 ) and low toxicity than existing two inhibitors ( Raltegravir , Elvitegravir). These inhibitor analogs will provide a platform for structure-based design of an additional class of inhibitors for antiviral therapy.
